Downregulating Long Non-coding RNAs CTBP1-AS2 Inhibits Colorectal Cancer Development by Modulating the miR-93-5p/TGF-β/SMAD2/3 Pathway

Qiankun Li, Wenjing Yue, Ming Li, Zhipeng Jiang, Zehui Hou, Wei Liu, Ning Ma, Wenchang Gan, Yingru Li, Taicheng Zhou, Shuang ChenFrontiers in Oncology 2021 · DOI

Abstract

Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Long non-coding RNAs (lncRNAs) have emerged as critical regulators of CRC progression, yet the role of CTBP1-AS2 remains poorly understood. Materials and Methods: CTBP1-AS2 and miR-93-5p expression were analyzed in CRC tissues and cell lines. Functional assays investigated the impact of CTBP1-AS2 on cell proliferation, invasion, and apoptosis. The mechanistic link between CTBP1-AS2, miR-93-5p, and the TGF-β/SMAD2/3 pathway was explored using bioinformatics and dual-luciferase reporter assays. Results: CTBP1-AS2 was significantly overexpressed in CRC and associated with poor patient survival. Functionally, CTBP1-AS2 promoted proliferation and invasion while inhibiting apoptosis. Mechanistically, CTBP1-AS2 acts as a competitive endogenous RNA (ceRNA) for miR-93-5p, thereby activating the TGF-β/SMAD2/3 signaling pathway. Conclusion: CTBP1-AS2 drives CRC development via the miR-93-5p/TGF-β/SMAD2/3 axis, suggesting its potential as a therapeutic target.

Introduction

Colorectal cancer (CRC) remains one of the most prevalent and lethal malignancies globally. Despite advancements in treatment, the molecular mechanisms driving its aggressive growth and metastasis are not fully understood. Recent research has highlighted the role of long non-coding RNAs (lncRNAs)—transcripts exceeding 200 nucleotides that lack protein-coding potential—as key regulatory "switches" in oncogenesis. This study investigates CTBP1-AS2, an lncRNA previously associated with metabolic disorders, to determine its functional significance and clinical relevance in CRC.

Methods

The study utilized a multi-disciplinary approach combining clinical data, in vitro cell biology, and in vivo animal models:

  • Clinical Correlation: CTBP1-AS2 expression was measured in 50 pairs of CRC and adjacent normal tissues using RT-PCR. Public datasets (TCGA via GEPIA) were used for external validation.
  • Functional Assays: CRC cell lines (SW620, HT29, etc.) were used for gain-of-function (overexpression) and loss-of-function (siRNA knockdown) experiments to observe changes in proliferation, colony formation, and invasion.
  • Mechanistic Verification: The competitive endogenous RNA (ceRNA) hypothesis was tested using Dual-Luciferase Reporter Assays and RNA Immunoprecipitation (RIP) to confirm binding between CTBP1-AS2 and miR-93-5p.
  • Animal Models: Nude mouse models were employed to evaluate the effect of CTBP1-AS2 levels on tumor volume and metastasis in a living system.

Results

CTBP1-AS2 Upregulation and Clinical Significance

Analysis of clinical samples revealed that CTBP1-AS2 is significantly overexpressed in CRC tissues compared to adjacent healthy tissues ($p < 0.001$). This finding was corroborated by TCGA data (COAD and READ datasets) and observed across multiple CRC cell lines relative to normal intestinal epithelial cells (FHC). Importantly, high CTBP1-AS2 expression was significantly correlated with reduced overall survival in patients ($p = 0.0321$).

CTBP1-AS2 expression profiles in CRC tissues and cell lines, and its correlation with patient survival. (A) Clinical tissue levels. (B) TCGA validation. (C) CRC cell line levels. (D) Kaplan-Meier survival curve.

Functional Impact on Tumor Progression

Silencing CTBP1-AS2 significantly inhibited the proliferation and invasive capacity of CRC cells. Conversely, overexpression of CTBP1-AS2 enhanced these malignant traits. Furthermore, knockdown of this lncRNA triggered apoptosis, evidenced by increased levels of pro-apoptotic proteins like Bax and cleaved Caspase-3. In vivo experiments confirmed that reducing CTBP1-AS2 levels led to smaller tumor volumes and a decrease in metastatic nodules in the lungs.

The miR-93-5p/TGF-β/SMAD2/3 Axis

Mechanistically, the study identified miR-93-5p as a direct target of CTBP1-AS2. In CRC, miR-93-5p is typically downregulated and acts as a tumor suppressor by inhibiting the TGF-β pathway. CTBP1-AS2 functions as a molecular "sponge," sequestering miR-93-5p and thereby releasing the inhibition of the TGF-β/SMAD2/3 signaling pathway. This activation drives the aggressive phenotype of CRC cells.

Discussion

The identification of the CTBP1-AS2/miR-93-5p/TGF-β/SMAD2/3 axis provides new insights into the molecular landscape of CRC. CTBP1-AS2 emerges not only as a driver of tumor growth and metastasis but also as a potent prognostic marker. While the TGF-β pathway has complex roles in cancer, this study demonstrates how it is hijacked by lncRNAs to promote advanced-stage progression. Future research should focus on the feasibility of targeting CTBP1-AS2 therapeutically and its potential use in non-invasive diagnostic screenings.

Summary updated

Abstract

<b>Background:</b> Colorectal cancer (CRC), the most commonly diagnosed cancer in the world, has a high mortality rate. In recent decades, long non-coding RNAs (lncRNAs) have been proven to exert an important effect on CRC growth. However, the CTBP1-AS2 expression and function in CRC are largely unknown. <b>Materials and Methods:</b> The CTBP1-AS2 and miR-93-5p expression in CRC and para-cancerous tissues was detected by reverse transcription-PCR. The expression of CTBP1-AS2, miR-93-5p and the transforming growth factor-beta (TGF-β)/small mothers against decapentaplegic 2/3 (SMAD2/3) pathway was selectively regulated to study the correlation between CTBP1-AS2 expression and prognosis of patients with CRC. CRC cell proliferation, apoptosis, and invasion were measured <i>in vivo</i> and <i>in vitro</i>. In addition, bioinformatics was applied to explore the targeting relationship between CTBP1-AS2 and miR-93-5p. The targeting binding sites between CTBP1-AS2 and miR-93-5p, as well as between miR-93-5p and TGF-β, were verified by the dual-luciferase reporter assay and the RNA immunoprecipitation experiment. <b>Results:</b> Compared with normal para-cancerous tissues, CTBP1-AS2 was considerably overexpressed in CRC tissues and was closely associated with worse survival of patients with CRC. Functionally, gain and loss in experiments illustrated that CTBP1-AS2 accelerated CRC cell proliferation and invasion and inhibited cell apoptosis. Mechanistically, CTBP1-AS2 regulated the malignant phenotype of tumor cells through the TGF-β/SMAD2/3 pathway. Moreover, miR-93-5p, as an endogenous competitive RNA of CTBP1-AS2, attenuated the oncogenic effects mediated by CTBP1-AS2. <b>Conclusion:</b> CTBP1-AS2 promotes the TGF-β/SMAD2/3 pathway activation by inhibiting miR-93-5p, thereby accelerating CRC development.
BibTeX
@inproceedings{li2021downregulating,
  author = {Qiankun Li and Wenjing Yue and Ming Li and Zhipeng Jiang and Zehui Hou and Wei Liu and Ning Ma and Wenchang Gan and Yingru Li and Taicheng Zhou and Wenjing Yue and Shuang Chen and Wenjing Yue and Shuang Chen},
  title = {{Downregulating Long Non-coding RNAs CTBP1-AS2 Inhibits Colorectal Cancer Development by Modulating the miR-93-5p/TGF-β/SMAD2/3 Pathway}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.626620},
}
Figure